Epiregulin: Roles in normal physiology and cancer

Seminars in Cell and Developmental Biology

Volumn 28, Issue , 2014, Pages 49-56

  Riese, David J ^a   Cullum, Richard L ^b  

^a AUBURN UNIVERSITY   (United States)

^b AUBURN UNIVERSITY   (United States)

Author keywords

EGF ErbB receptors; Epiregulin; Epithelial cell proliferation; Inflammation; Oocyte maturation; Tumor progression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIREGULIN; EPIDERMAL GROWTH FACTOR;

ANGIOGENESIS; BLADDER CANCER; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; COLON CANCER; COLORECTAL CANCER; CORNEA INJURY; DERMATITIS; EPITHELIUM CELL; HEAD AND NECK CANCER; HUMAN; INFLAMMATION; INTESTINE EPITHELIUM CELL; LIVER CANCER; LIVER REGENERATION; LUNG CANCER; MOLECULAR CLONING; NEOPLASM; NONHUMAN; OOCYTE DEVELOPMENT; OOCYTE MATURATION; OVARY FOLLICLE DEVELOPMENT; PHYSIOLOGY; PROTEIN BINDING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SKIN INJURY; STOMACH CANCER; TISSUE REPAIR; WOUND HEALING; ANIMAL; METABOLISM;

ANIMALS; CELL PROLIFERATION; EPIDERMAL GROWTH FACTOR; EPIREGULIN; HUMANS; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84901246389     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2014.03.005     Document Type: Review

References (102)

1. Lim H., Dey S.K., Das S.K. Differential expression of the erbB2 gene in the periimplantation mouse uterus: potential mediator of signaling by epidermal growth factor-like growth factors. Endocrinology 1997, 138:1328-1337.
2. Normanno N., Bianco C., De Luca A., Salomon D.S. The role of EGF-related peptides in tumor growth. Front Biosci 2001, 6:D685-D707.
3. Ocana A., Pandiella A. Targeting HER receptors in cancer. Curr Pharm Des 2013, 19:808-817.
4. Patel R., Leung H.Y. Targeting the EGFR-family for therapy: biological challenges and clinical perspective. Curr Pharm Des 2012, 18:2672-2679.
5. Riese D.J. Ligand-based receptor tyrosine kinase partial agonists: new paradigm for cancer drug discovery?. Expert Opin Drug Discovery 2011, 6:185-193.
6. Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res: Off J Ital Pharmacol Soc 2014, 79:34-74.
7. Wilson K.J., Gilmore J.L., Foley J., Lemmon M.A., Riese D.J. Functional selectivity of EGF family peptide growth factors: implications for cancer. Pharmacol Ther 2009, 122:1-8.
8. Harris R.C., Chung E., Coffey R.J. EGF receptor ligands. Exp Cell Res 2003, 284:2-13.
9. Schneider M.R., Wolf E. The epidermal growth factor receptor ligands at a glance. J Cell Physiol 2009, 218:460-466.
10. Toyoda H., Komurasaki T., Uchida D., Takayama Y., Isobe T., Okuyama T., et al. Epiregulin. A novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 1995, 270:7495-7500.
11. Komurasaki T., Toyoda H., Uchida D., Morimoto S. Epiregulin binds to epidermal growth factor receptor and ErbB-4 and induces tyrosine phosphorylation of epidermal growth factor receptor, ErbB-2, ErbB-3 and ErbB-4. Oncogene 1997, 15:2841-2848.
12. Riese D.J., Komurasaki T., Plowman G.D., Stern D.F. Activation of ErbB4 by the bifunctional epidermal growth factor family hormone epiregulin is regulated by ErbB2. J Biol Chem 1998, 273:11288-11294.
13. Shelly M., Pinkas-Kramarski R., Guarino B.C., Waterman H., Wang L.M., Lyass L., et al. Epiregulin is a potent pan-ErbB ligand that preferentially activates heterodimeric receptor complexes. J Biol Chem 1998, 273:10496-10505.
14. Toyoda H., Komurasaki T., Uchida D., Morimoto S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J 1997, 326:69-75.
15. Riese D.J., Bermingham Y., van Raaij T.M., Buckley S., Plowman G.D., Stern D.F. Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor or neuregulin-beta. Oncogene 1996, 12:345-353.
16. Elenius K., Paul S., Allison G., Sun J., Klagsbrun M. Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation. EMBO J 1997, 16:1268-1278.
17. Gilmore J.L., Gallo R.M., Riese D.J. The epidermal growth factor receptor (EGFR)-S442F mutant displays increased affinity for neuregulin-2beta and agonist-independent coupling with downstream signalling events. Biochem J 2006, 396:79-88.
18. Toyoda H., Komurasaki T., Ikeda Y., Yoshimoto M., Morimoto S. Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development. FEBS Lett 1995, 377:403-407.
19. Conti M., Hsieh M., Park J.-Y., Su Y.-Q. Role of the epidermal growth factor network in ovarian follicles. Mol Endocrinol 2006, 20:715-723.
20. Lee D., Pearsall R.S., Das S., Dey S.K., Godfrey V.L., Threadgill D.W. Epiregulin is not essential for development of intestinal tumors but is required for protection from intestinal damage. Mol Cell Biol 2004, 24:8907-8916.
21. Hobbs S.S., Coffing S.L., Le A.T., Cameron E.M., Williams E.E., Andrew M., et al. Neuregulin isoforms exhibit distinct patterns of ErbB family receptor activation. Oncogene 2002, 21:8442-8452.
22. Hobbs S.S., Cameron E.M., Hammer R.P., Le A.T., Gallo R.M., Blommel E.N., et al. Five carboxyl-terminal residues of neuregulin2 are critical for stimulation of signaling by the ErbB4 receptor tyrosine kinase. Oncogene 2004, 23:883-893.
23. Hobbs S.S., Gallo R.M., Riese D.J. Phe45 of NRG2beta is critical for the affinity of NRG2beta for ErbB4 and for potent stimulation of ErbB4 signaling by NRG2beta*. Growth Factors 2005, 23:273-283.
24. Wilson K.J., Mill C.P., Cameron E.M., Hobbs S.S., Hammer R.P., Riese D.J. Inter-conversion of neuregulin2 full and partial agonists for ErbB4. Biochem Biophys Res Commun 2007, 364:351-357.
25. Wilson K.J., Mill C.P., Gallo R.M., Cameron E.M., VanBrocklin H., Settleman J., et al. The Q43L mutant of neuregulin 2beta is a pan-ErbB receptor antagonist. Biochem J 2012, 443:133-144.
26. Wilson K.J., Mill C., Lambert S., Buchman J., Wilson T.R., Hernandez-Gordillo V., et al. EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors 2012, 30:107-116.
27. Komurasaki T., Toyoda H., Uchida D., Nemoto N. Mechanism of growth promoting activity of epiregulin in primary cultures of rat hepatocytes. Growth Factors 2002, 20:61-69.
28. Roepstorff K., Grandal M.V., Henriksen L., Knudsen S.L.J., Lerdrup M., Grovdal L., et al. Differential effects of EGFR ligands on endocytic sorting of the receptor. Traffic 2009, 10:1115-1127.
29. Taylor D.S., Cheng X., Pawlowski J.E., Wallace A.R., Ferrer P., Molloy C.J. Epiregulin is a potent vascular smooth muscle cell-derived mitogen induced by angiotensin II, endothelin-1, and thrombin. Proc Natl Acad Sci U S A 1999, 96:1633-1638.
30. Liebmann C. EGF receptor activation by GPCRs: an universal pathway reveals different versions. Mol Cell Endocrinol 2011, 331:222-231.
31. Koo B.-H., Kim D.-S. Factor Xa induces mitogenesis of vascular smooth muscle cells via autocrine production of epiregulin. J Biol Chem 2003, 278:52578-52586.
32. Takahashi M., Ki H., Yoshida K., Ohkawa Y., Komurasaki T., Kitabatake A., et al. Epiregulin as a major autocrine/paracrine factor released from ERK- and p38MAPK-activated vascular smooth muscle cells. Circulation 2003, 108:2524-2529.
33. White G.E., Tan T.C.C., John A.E., Whatling C., McPheat W.L., Greaves D.R. Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling. Cardiovasc Res 2010, 85:825-835.
34. Kyotani Y., Ota H., Itaya-Hironaka A., Yamauchi A., Sakuramoto-Tsuchida S., Zhao J., et al. Intermittent hypoxia induces the proliferation of rat vascular smooth muscle cell with the increases in epidermal growth factor family and erbB2 receptor. Exp Cell Res 2013, 319:3042-3050.
35. Berasain C., Garcia-Trevijano E.R., Castillo J., Erroba E., Santamaria M., Lee D.C., et al. Novel role for amphiregulin in protection from liver injury. J Biol Chem 2005, 280:19012-19020.
36. Shirakata Y., Komurasaki T., Toyoda H., Hanakawa Y., Yamasaki K., Tokumaru S., et al. Epiregulin, a novel member of the epidermal growth factor family, is an autocrine growth factor in normal human keratinocytes. J Biol Chem 2000, 275:5748-5753.
37. Shirasawa S., Sugiyama S., Baba I., Inokuchi J., Sekine S., Ogino K., et al. Dermatitis due to epiregulin deficiency and a critical role of epiregulin in immune-related responses of keratinocyte and macrophage. Proc Natl Acad Sci U S A 2004, 101:13921-13926.
38. Sugiyama S., Nakabayashi K., Baba I., Sasazuki T., Shirasawa S. Role of epiregulin in peptidoglycan-induced proinflammatory cytokine production by antigen presenting cells. Biochem Biophys Res Commun 2005, 337:271-274.
39. Roy S., Khanna S., Rink C., Biswas S., Sen C.K. Characterization of the acute temporal changes in excisional murine cutaneous wound inflammation by screening of the wound-edge transcriptome. Physiol Genomics 2008, 34:162-184.
40. Robert C., Gagne D., Bousquet D., Barnes F.L., Sirard M.A. Differential display and suppressive subtractive hybridization used to identify granulosa cell messenger RNA associated with bovine oocyte developmental competence. Biol Reprod 2001, 64:1812-1820.
41. Sekiguchi T., Mizutani T., Yamada K., Yazawa T., Kawata H., Yoshino M., et al. Transcriptional regulation of the epiregulin gene in the rat ovary. Endocrinology 2002, 143:4718-4729.
42. Park J.-Y., Su Y.-Q., Ariga M., Law E., Jin S.L.C., Conti M. EGF-like growth factors as mediators of LH action in the ovulatory follicle. Science 2004, 303:682-684.
43. Freimann S., Ben-Ami I., Dantes A., Armon L., Ben Ya'cov-Klein A., Ron-El R., et al. Differential expression of genes coding for EGF-like factors and ADAMTS1 following gonadotropin stimulation in normal and transformed human granulosa cells. Biochem Biophys Res Commun 2005, 333:935-943.
44. Yamashita Y., Kawashima I., Yanai Y., Nishibori M., Richards J.S., Shimada M. Hormone-induced expression of tumor necrosis factor alpha-converting enzyme/A disintegrin and metalloprotease-17 impacts porcine cumulus cell oocyte complex expansion and meiotic maturation via ligand activation of the epidermal growth factor receptor. Endocrinology 2007, 148:6164-6175.
45. Luetteke N.C., Qiu T.H., Fenton S.E., Troyer K.L., Riedel R.F., Chang A., et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development 1999, 126:2739-2750.
46. Hsieh M., Lee D., Panigone S., Horner K., Chen R., Theologis A., et al. Luteinizing hormone-dependent activation of the epidermal growth factor network is essential for ovulation. Mol Cell Biol 2007, 27:1914-1924.
47. Das S.K., Das N., Wang J., Lim H., Schryver B., Plowman G.D., et al. Expression of betacellulin and epiregulin genes in the mouse uterus temporally by the blastocyst solely at the site of its apposition is coincident with the "window" of implantation. Dev Biol 1997, 190:178-190.
48. Song H., Lim H., Das S.K., Paria B.C., Dey S.K. Dysregulation of EGF family of growth factors and COX-2 in the uterus during the preattachment and attachment reactions of the blastocyst with the luminal epithelium correlates with implantation failure in LIF-deficient mice. Mol Endocrinol 2000, 14:1147-1161.
49. Vermeer P.D., Panko L., Karp P., Lee J.H., Zabner J. Differentiation of human airway epithelia is dependent on erbB2. Am J Physiol Lung Cell Mol Physiol 2006, 291:L175-L180.
50. Patel R.D., Kim D.J., Peters J.M., Perdew G.H. The aryl hydrocarbon receptor directly regulates expression of the potent mitogen epiregulin. Toxicol Sci 2006, 89:75-82.
51. Chu E.K., Foley J.S., Cheng J., Patel A.S., Drazen J.M., Tschumperlin D.J. Bronchial epithelial compression regulates epidermal growth factor receptor family ligand expression in an autocrine manner. Am J Respir Cell Mol Biol 2005, 32:373-380.
52. Liu K., Gualano R.C., Hibbs M.L., Anderson G.P., Bozinovski S. Epidermal growth factor receptor signaling to Erk1/2 and STATs control the intensity of the epithelial inflammatory responses to rhinovirus infection. J Biol Chem 2008, 283:9977-9985.
53. Arae K., Hirata M., Kurata S., Kamiya S., Taguchi H. Mycoplasma pneumoniae induces interleukin-8 production via the epidermal growth factor receptor pathway. Microbiol Immunol 2011, 55:748-750.
54. Thuong N.T.T., Hawn T.R., Chau T.T.H., Bang N.D., Yen N.T.B., Thwaites G.E., et al. Epiregulin (EREG) variation is associated with susceptibility to tuberculosis. Genes Immun 2012, 13:275-281.
55. Lahoti T.S., Hughes J.M., Kusnadi A., John K., Zhu B., Murray I.A., et al. Aryl hydrocarbon receptor antagonism attenuates growth factor expression, proliferation, and migration in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Pharmacol Exp Ther 2014, 348:236-245.
56. Zhou M., Li X-m, Lavker R.M. Transcriptional profiling of enriched populations of stem cells versus transient amplifying cells. A comparison of limbal and corneal epithelial basal cells. J Biol Chem 2006, 281:19600-19609.
57. Morita S.-i., Shirakata Y., Shiraishi A., Kadota Y., Hashimoto K., Higashiyama S., et al. Human corneal epithelial cell proliferation by epiregulin and its cross-induction by other EGF family members. Mol Vis 2007, 13:2119-2128.
58. Zhang Y., Kobayashi T., Hayashi Y., Yoshioka R., Shiraishi A., Shirasawa S., et al. Important role of epiregulin in inflammatory responses during corneal epithelial wound healing. Invest Ophthalmol Vis Sci 2012, 53:2414-2423.
59. Yusta B., Holland D., Koehler J.A., Maziarz M., Estall J.L., Higgins R., et al. ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut. Gastroenterology 2009, 137:986-996.
60. Inatomi O., Andoh A., Yagi Y., Bamba S., Tsujikawa T., Fujiyama Y. Regulation of amphiregulin and epiregulin expression in human colonic subepithelial myofibroblasts. Int J Mol Med 2006, 18:497-503.
61. Hsu D., Fukata M., Hernandez Y.G., Sotolongo J.P., Goo T., Maki J., et al. Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest 2010, 90:1295-1305.
62. Brandl K., Sun L., Neppl C., Siggs O.M., Le Gall S.M., Tomisato W., et al. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc Natl Acad Sci U S A 2010, 107:19967-19972.
63. Thogersen V.B., Sorensen B.S., Poulsen S.S., Orntoft T.F., Wolf H., Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001, 61:6227-6233.
64. Nicholson B.E., Frierson H.F., Conaway M.R., Seraj J.M., Harding M.A., Hampton G.M., et al. Profiling the evolution of human metastatic bladder cancer. Cancer Res 2004, 64:7813-7821.
65. Ornskov D., Nexo E., Sorensen B.S. Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system. FEBS J 2006, 273:5479-5489.
66. Ornskov D., Nexo E., Sorensen B.S. Insulin induces a transcriptional activation of epiregulin, HB-EGF and amphiregulin, by a PI3K-dependent mechanism: identification of a specific insulin-responsive promoter element. Biochem Biophys Res Commun 2007, 354:885-891.
67. Li X., Massa P.E., Hanidu A., Peet G.W., Aro P., Savitt A., et al. IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program. J Biol Chem 2002, 277:45129-45140.
68. Orso F., Penna E., Cimino D., Astanina E., Maione F., Valdembri D., et al. AP-2alpha and AP-2gamma regulate tumor progression via specific genetic programs. FASEB J 2008, 22:2702-2714.
69. Wu W.K.K., Tse T.T.M., Sung J.J.Y., Li Z.J., Yu L., Cho C.H. Expression of ErbB receptors and their cognate ligands in gastric and colon cancer cell lines. Anticancer Res 2009, 29:229-234.
70. Nakagawa M., Nabeshima K., Asano S., Hamasaki M., Uesugi N., Tani H., et al. Up-regulated expression of ADAM17 in gastrointestinal stromal tumors: coexpression with EGFR and EGFR ligands. Cancer Sci 2009, 100:654-662.
71. Oshima H., Popivanova B.K., Oguma K., Kong D., Ishikawa T.-o., Oshima M. Activation of epidermal growth factor receptor signaling by the prostaglandin E(2) receptor EP4 pathway during gastric tumorigenesis. Cancer Sci 2011, 102:713-719.
72. Fang L., Cheng J.C., Chang H.M., Sun Y.P., Leung P.C. EGF-like growth factors induce COX-2-derived PGE2 production through ERK1/2 in human granulosa cells. J Clin Endocrinol Metab 2013, 98:4932-4941.
73. Sawaoka H., Kawano S., Tsuji S., Tsujii M., Gunawan E.S., Takei Y., et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998, 274:G1061-G1067.
74. Cho S.J., Kim N., Kim J.S., Jung H.C., Song I.S. The anti-cancer effect of COX-2 inhibitors on gastric cancer cells. Dig Dis Sci 2007, 52:1713-1721.
75. Settleman J. Oncogene addiction. Curr Biol 2012, 22:R43-R44.
76. Sharma S.V., Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007, 21:3214-3231.
77. Khambata-Ford S., Garrett C.R., Meropol N.J., Basik M., Harbison C.T., Wu S., et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25:3230-3237.
78. Jacobs B., De Roock W., Piessevaux H., Van Oirbeek R., Biesmans B., De Schutter J., et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2009, 27:5068-5074.
79. Baker J.B., Dutta D., Watson D., Maddala T., Munneke B.M., Shak S., et al. Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 2011, 104:488-495.
80. Krumbach R., Schuler J., Hofmann M., Giesemann T., Fiebig H.-H., Beckers T. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer 2011, 47:1231-1243.
81. Yoshida M., Shimura T., Sato M., Ebi M., Nakazawa T., Takeyama H., et al. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol 2013, 139:367-378.
82. Neufert C., Becker C., Tureci O., Waldner M.J., Backert I., Floh K., et al. Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest 2013, 123:1428-1443.
83. Watanabe T., Kobunai T., Yamamoto Y., Kanazawa T., Konishi T., Tanaka T., et al. Prediction of liver metastasis after colorectal cancer using reverse transcription-polymerase chain reaction analysis of 10 genes. Eur J Cancer 2010, 46:2119-2126.
84. IJ N., Rijnierse A., de Wit N., Jonker-Termont D., Dekker J., Muller M., et al. Dietary haem stimulates epithelial cell turnover by downregulating feedback inhibitors of proliferation in murine colon. Gut 2012, 61:1041-1049.
85. Gupta R.A., Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1:11-21.
86. McIntyre E., Blackburn E., Brown P.J., Johnson C.G., Gullick W.J. The complete family of epidermal growth factor receptors and their ligands are co-ordinately expressed in breast cancer. Breast Cancer Res Treat 2010, 122:105-110.
87. Hayashida T., Takahashi F., Chiba N., Brachtel E., Takahashi M., Godin-Heymann N., et al. HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis. Proc Natl Acad Sci U S A 2010, 107:1100-1105.
88. Christofori G. Cancer: division of labour. Nature 2007, 446:735-736.
89. Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007, 446:765-770.
90. Vlaicu P., Mertins P., Mayr T., Widschwendter P., Ataseven B., Hogel B., et al. Monocytes/macrophages support mammary tumor invasivity by co-secreting lineage-specific EGFR ligands and a STAT3 activator. BMC Cancer 2013, 13:197.
91. Zhang J., Iwanaga K., Choi K.C., Wislez M., Raso M.G., Wei W., et al. Intratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cells. Cancer Prev Res (Phila, PA) 2008, 1:201-207.
92. Kometani T., Yoshino I., Miura N., Okazaki H., Ohba T., Takenaka T., et al. Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway. Cancer Lett 2009, 278:27-33.
93. John K., Lahoti T.S., Wagner K., Hughes J.M., Perdew G.H. The Ah receptor regulates growth factor expression in head and neck squamous cell carcinoma cell lines. Mol Carcinog 2013.
94. Sunaga N., Kaira K., Imai H., Shimizu K., Nakano T., Shames D.S., et al. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer. Oncogene 2013, 32:4034-4042.
95. Shigeishi H., Higashikawa K., Hiraoka M., Fujimoto S., Mitani Y., Ohta K., et al. Expression of epiregulin, a novel epidermal growth factor ligand associated with prognosis in human oral squamous cell carcinomas. Oncol Rep 2008, 19:1557-1564.
96. Oshima G., Wennerberg J., Yamatodani T., Kjellen E., Mineta H., Johnsson A., et al. Autocrine epidermal growth factor receptor ligand production and cetuximab response in head and neck squamous cell carcinoma cell lines. J Cancer Res Clin Oncol 2012, 138:491-499.
97. Zhao M., He H-w, Sun H-x, Ren K-h, Shao R-g. Dual knockdown of N-ras and epiregulin synergistically suppressed the growth of human hepatoma cells. Biochem Biophys Res Commun 2009, 387:239-244.
98. Dapito D.H., Mencin A., Gwak G.Y., Pradere J.P., Jang M.K., Mederacke I., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 2012, 21:504-516.
99. Darnaud M., Faivre J., Moniaux N. Targeting gut flora to prevent progression of hepatocellular carcinoma. J Hepatol 2013, 58:385-387.
100. Yamamoto T., Akisue T., Marui T., Nakatani T., Kawamoto T., Hitora T., et al. Expression of betacellulin, heparin-binding epidermal growth factor and epiregulin in human malignant fibrous histiocytoma. Anticancer Res 2004, 24:2007-2010.
101. Zhu Z., Kleeff J., Friess H., Wang L., Zimmermann A., Yarden Y., et al. Epiregulin is up-regulated in pancreatic cancer and stimulates pancreatic cancer cell growth. Biochem Biophys Res Commun 2000, 273:1019-1024.
102. Stonecypher M.S., Chaudhury A.R., Byer S.J., Carroll S.L. Neuregulin growth factors and their ErbB receptors form a potential signaling network for schwannoma tumorigenesis. J Neuropathol Exp Neurol 2006, 65:162-175.